Theravance has appointed Dr. Brett Haumann as Vice President of Clinical Development, Respiratory. Prior to joining Theravance, Haumann served as Chief Medical officer at Circassia Limited. Previously, he served as Vice President of Clinical Development (2007-2012) and Director of Clinical Development (2002-2007) at GlaxoSmithKline. From 1997-2001, Haumann was Medical Advisor at Glaxo Wellcome in South Africa and the United Kingdom. His early career was spent at Anglo American Corporation in South Africa, where he served as Medical Officer.
Haumann received his Bachelor in Medicine and Surgery (MBBCh) from the University of Witwatersrand Medical School and his M.B.A. from Open University.
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: RELVAR® ELLIPTA® or BREO® ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at www.theravance.com.